Decentralized clinical trial models regulation

Introduction

Decentralized Clinical Trials (DCTs) are clinical research studies in which some or most trial-related activities are conducted away from traditional clinical trial sites. Instead of requiring participants to visit hospitals or research centres for every activity, decentralized models use digital technologies, telemedicine, mobile healthcare professionals, home-based sample collection, wearable devices, and electronic data collection systems.

These models have become increasingly important in pharmaceutical research, biotechnology, medical device development, and personalised medicine. They allow researchers to recruit participants from different geographical locations and reduce the practical difficulties associated with frequent hospital visits.

However, decentralized clinical trials create regulatory challenges concerning informed consent, patient safety, medical supervision, data protection, electronic records, clinical accountability, and cross-border research activities. Therefore, appropriate legal frameworks are necessary to ensure that decentralized trials maintain the same ethical and scientific standards as conventional clinical trials.

Legal framework governing decentralized clinical trials in India

India regulates clinical trials primarily through the Drugs and Cosmetics Act, 1940, the New Drugs and Clinical Trials Rules, 2019 (NDCTR), and applicable ethical guidelines.

1. New Drugs and Clinical Trials Rules, 2019

The NDCTR establishes requirements concerning clinical trial permissions, ethics committee approval, informed consent, participant safety, and compensation for trial-related injury or death.

These requirements remain relevant when clinical trial activities are conducted through decentralized arrangements. Using digital platforms or home-based procedures does not remove the obligation to comply with applicable clinical trial regulations.

2. Drugs and Cosmetics Act, 1940

The Act provides the statutory foundation for regulating drugs and clinical investigations in India. Clinical trials involving new drugs must comply with the applicable approval and regulatory requirements.

3. Information Technology Act, 2000

The Act provides legal recognition to electronic records and electronic transactions. It is relevant to electronic consent documentation, digital clinical records, and electronic communication between participants and research institutions.

4. Digital Personal Data Protection Act, 2023

The Act is relevant when decentralized clinical trials process digital personal data, including identifiable participant information. Its provisions apply subject to applicable commencement requirements and rules.

5. ICMR National Ethical Guidelines, 2017

The Indian Council of Medical Research guidelines establish ethical principles for biomedical and health research involving human participants. They address informed consent, confidentiality, participant welfare, and ethical review.

International regulatory framework

Several international frameworks influence the regulation of decentralized clinical trials.

ICH Good Clinical Practice (E6): Establishes internationally recognised standards for clinical trial design, conduct, documentation, and reporting. The revised ICH E6(R3) guideline strengthens risk-based quality management and modern trial oversight.

US FDA guidance on Decentralized Clinical Trials: Provides recommendations concerning remote trial activities, informed consent, investigational products, safety monitoring, and digital technologies.

European Union Clinical Trials Regulation 536/2014: Establishes requirements for clinical trials conducted within the European Union.

General Data Protection Regulation (GDPR): Governs the processing of personal data, including health information, within its applicable scope.

Declaration of Helsinki: Provides internationally recognised ethical principles for medical research involving human participants.

Major decentralized clinical trial models

Decentralized clinical trials can operate through different arrangements depending on the nature of the research and the medical requirements of participants.

1. Fully decentralized trials

In this model, most trial activities take place outside conventional research facilities. Participants may use digital platforms, remote consultations, and home-based services.

2. Hybrid clinical trials

Hybrid trials combine traditional hospital visits with remote activities. For example, participants may attend hospitals for major medical examinations while completing routine questionnaires and follow-up consultations remotely.

3. Site-less clinical trials

These trials rely heavily on digital systems, remote healthcare professionals, and decentralised service providers rather than traditional physical research centres.

4. Mobile healthcare-based trials

Healthcare professionals visit participants at their homes or other approved locations to conduct specific clinical assessments, collect samples, or monitor health conditions.

Regulatory requirements for decentralized clinical trials

1. Informed consent

Participants must receive adequate information about the research, potential risks, benefits, and their rights. Electronic informed consent may be used where legally and ethically acceptable, provided that the process satisfies applicable requirements.

2. Ethics committee approval

The appropriate ethics committee must review the research protocol and relevant participant-protection arrangements. Changes involving remote monitoring, digital consent, or home-based procedures may require additional review or approval.

3. Patient safety and medical supervision

Decentralized trials must establish procedures for identifying adverse events, arranging emergency medical assistance, and maintaining appropriate medical supervision.

4. Data protection and confidentiality

Trial sponsors and investigators must protect participant information collected through wearable devices, mobile applications, telemedicine platforms, and electronic health records.

5. Investigational medicinal products

The distribution, storage, transportation, and administration of investigational products must comply with applicable regulatory requirements. Remote delivery arrangements must preserve product quality and participant safety.

6. Documentation and audit trails

Sponsors should maintain reliable electronic records showing consent, clinical observations, safety reports, protocol deviations, and trial-related decisions.

Important case laws

Direct Indian judicial decisions specifically addressing decentralized clinical trial models remain limited. However, the following cases establish important principles concerning clinical research, informed consent, medical confidentiality, and patient autonomy.

1. Samira Kohli v. Dr. Prabha Manchanda (2008)

The Supreme Court examined the requirements of informed consent in medical treatment. It held that valid consent must be based on adequate information and must relate to the proposed medical procedure.

The judgment is relevant to decentralized clinical trials because electronic consent and remote recruitment must ensure that participants genuinely understand the research procedures, associated risks, and available alternatives.

2. K.S. Puttaswamy v. Union of India (2017)

The Supreme Court recognised privacy as a fundamental right under Article 21. It established that interference with privacy must satisfy legality, legitimate purpose, and proportionality.

This judgment is particularly relevant to decentralized trials because wearable devices, mobile applications, and remote monitoring platforms may collect extensive personal health information.

3. Mr. X v. Hospital Z (1998)

The Supreme Court considered medical confidentiality and recognised that confidentiality is important but not absolute in every circumstance.

The judgment is relevant by analogy when decentralized clinical trial information must be disclosed for legitimate medical or legal purposes. Such disclosures should remain appropriately justified.

4. Jacob Mathew v. State of Punjab (2005)

The Supreme Court examined the standards governing medical negligence and the criminal liability of medical professionals. It discussed the importance of professional competence and appropriate standards of medical care.

The judgment is relevant to decentralized clinical trials because remote medical supervision must maintain appropriate professional standards and should not compromise participant safety.

5. Indian Medical Association v. V.P. Shantha (1995)

The Supreme Court examined the applicability of consumer protection law to medical services. It clarified circumstances in which medical services fall within the scope of consumer protection legislation.

The decision is relevant to decentralized clinical trial arrangements because participants may receive medical services through hospitals, clinics, and healthcare professionals operating under contractual or institutional arrangements. Its application will depend on the facts and the legal relationship involved.

Challenges in regulating decentralized clinical trials

Decentralized clinical trials create several legal and operational challenges.

Digital inequality: Participants may lack reliable internet access or suitable digital devices.

Data security: Remote platforms may expose confidential medical information to cybersecurity risks.

Consent verification: Researchers must ensure that electronic consent is properly obtained and documented.

Medical supervision: Remote monitoring may delay the identification of serious medical complications.

Regulatory jurisdiction: Trials involving multiple countries may face different legal requirements.

Data reliability: Wearable devices and home-based measurements may produce inconsistent results.

Accountability: Responsibilities among sponsors, investigators, hospitals, and technology providers must be clearly defined.

Safeguards and regulatory recommendations

Regulatory authorities should establish clear requirements for remote clinical activities, electronic consent, participant identification, medical supervision, and digital record management.

Sponsors should conduct risk assessments before adopting decentralized procedures. Ethics committees should evaluate whether remote monitoring and home-based activities are appropriate for the particular research population and investigational product.

Additionally, trial protocols should identify emergency medical arrangements, adverse-event reporting procedures, data access responsibilities, and arrangements for protecting participants who experience technical difficulties.

Conclusion

Decentralized clinical trial models offer significant opportunities to improve research accessibility, participant convenience, and the geographical reach of clinical studies. However, these advantages must be balanced against patient safety, informed consent, medical confidentiality, and data protection. India's New Drugs and Clinical Trials Rules, 2019, provide an important regulatory foundation, while international GCP standards offer additional guidance. Clear regulatory procedures, effective ethics committee oversight, secure digital systems, and appropriate medical supervision are essential for the responsible development of decentralized clinical trials.